International Study of Biofield Therapy

• Sponsor: MOA Health Science Foundation (Other)
• Overall Status: Completed
• CT.gov ID: NCT03994809
• Collaborator: (none)
• Enrollment: 12,000
• Actual Duration (Months): 33

Study Details

Study Description

Brief Summary

Participants from 14 different countries received a single session of biofield therapy (Okada Purifying Therapy) lasting 30 minutes or longer from the volunteer practitioners. Before and after the therapy, they reported the severity of physical pain, anxiety/depression, dizziness/palpitation, and overall symptoms. The team compared the effectiveness/safety of biofield therapy between countries and analyzed the factors associated with the outcomes.

Condition or Disease	Intervention/Treatment	Phase
Pain; Depression, Anxiety; Dizziness; Signs and Symptoms	Other: Okada Purifying Therapy

Detailed Description

Participants aged 16 or older from 14 different countries (Japan, USA, Argentina, Brazil, Chile, Mexico, Peru, Taiwan, Thai, South Korea, Belgium, France, Portugal, and Spain) received a single session of biofield therapy (Okada Purifying Therapy) lasting 30 minutes or longer from the volunteer practitioners in their country of residence. Before and after the intervention, they reported each severity level of physical pain, anxiety/depression, dizziness/palpitation, and overall symptoms. The team compared the improvement/exacerbation rate of a single session of biofield therapy between the countries, and examined the adjusted odds ratio of the variables associated with the changes in each category of symptoms in a real-world setting.

Study Design

• Study Type: Observational
• Actual Enrollment: 12000 participants
• Observational Model: Case-Only
• Time Perspective: Cross-Sectional
• Official Title: International Cross-sectional Study on the Effectiveness of Biofield Therapy for the Relief of Various Symptoms
• Actual Study Start Date: Jan 1, 2008
• Actual Primary Completion Date: Sep 30, 2010
• Actual Study Completion Date: Sep 30, 2010

Outcome Measures

Primary Outcome Measures

1. improvement/exacerbation rate of symptoms after a single session of biofield therapy [Up to one year after all the data were collected.]

   The Mann-Whitney test was conducted to compare the improvement/exacerbation rates between countries.

2. adjusted odds ratio of the factors associated with the changes in symptoms [Up to one year after all the data were collected.]

   Logistic regression analyses

Eligibility Criteria

Criteria

• Ages Eligible for Study: 16 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Individuals who agreed to receive a single session of biofield therapy for 30 minutes or longer from the volunteer investigators.

2. Individuals who were able to self-evaluate the change of their symptoms.

3. Individuals who were competent to answer the questionnaires.

4. Individuals who were aged 16 or older.

Exclusion Criteria:

• no specific exclusion criteria

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• MOA Health Science Foundation

Investigators

• Study Chair: Kiyoshi Suzuki, MD, PhD, MOA Health Science Foundation

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Kiyoshi Suzuki, President, MOA Health Science Foundation
• ClinicalTrials.gov Identifier: NCT03994809
• Other Study ID Numbers: MOA-004
• First Posted: Jun 21, 2019
• Last Update Posted: Jun 21, 2019
• Last Verified: Jun 1, 2019

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Kiyoshi Suzuki, President, MOA Health Science Foundation: biofield therapy; ethnic differences; Okada Purifying Therapy; effectiveness; safety
• Additional relevant MeSH terms: Dizziness

Study Results

No Results Posted as of Jun 21, 2019